Your Health, We Care
Release date: 2026-03-13 16:39:03 Recommended: 90
Capmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibitor that specifically inhibits MET receptors and the phosphorylation process of MET-mediated downstream signaling proteins, thereby suppressing the proliferation and migration of c-MET-dependent tumor cells and inducing their apoptosis. Clinically, it is used for the treatment of adult patients with metastatic non-small cell lung cancer. This drug has the ability to penetrate the blood-brain barrier and demonstrates certain inhibitory effects on brain tumor lesions.
Currently, multiple versions of Capmatinib (Tabrecta) are available on the market, with pricing varying across versions:
The generic version of Capmatinib produced by Lao Lucius Pharmaceuticals is available in a specification of 200mg × 60 tablets per box. Based on current market information, its price is approximately between $2,650 and $3,100 per box.
The original Novartis version offers two specifications: 200mg60 capsules and 150mg60 capsules, with prices ranging from approximately $4,282 to $62,100.
The above prices are for reference only. The actual selling price of Capmatinib may fluctuate due to multiple factors such as exchange rate changes, sales region, drug version, and purchasing channels. Given the uncertainty in pricing, it is recommended to verify the latest quotes before purchasing. Additionally, it is essential to ensure that the medication is obtained through legitimate channels.
The main purchasing channels for Lucius Pharmaceuticals Capmatinib (Tabrecta) are as follows:
In regions where the drug has been approved for marketing, patients can purchase it directly from hospital pharmacies with a doctor's prescription.
Legitimate and licensed online pharmacies may offer this drug. It is necessary to confirm that the website holds a valid license for pharmaceutical sales and to carefully verify the source of the medication.
Some large retail pharmacy chains may stock the drug. Patients can inquire at nearby pharmacies for specific availability.
Patients can consult domestic medical institutions to inquire whether they can assist in purchasing the required version of Capmatinib and obtain the latest pricing information.
Common side effects observed in the clinical use of Capmatinib include:
As a frequent side effect, it often manifests as swelling in the hands, feet, and face.
A typical gastrointestinal reaction, often accompanied by loss of appetite, which may affect nutritional intake and quality of life.
If severe and left untreated, vomiting may lead to dehydration and other complications.
Patients may experience persistent tiredness and weakness, which can impact daily activities.
During the medication period, patients must strictly follow the doctor's guidance. If side effects occur, they should promptly inform their doctor to ensure timely and appropriate management.
